Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1%
Saved in:
| Published in: | Health Economics Review |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Pooled survival and cost-effectiveness analysis of immune checkpoint inhibitors-based for metastatic non-small-cell lung cancer with PD-L1 lower than 1%
- PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure
- Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
- Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study
- The potential role of exercise in mitigating fertility toxicity associated with immune checkpoint inhibitors (ICIs) in cancer patients
- Cryoablation Plus Immune Checkpoint Inhibitors Enhanced Dendritic Cell and T Cell Activation in TNBC Murine Model
- Oncolytic virus and PD-1/PD-L1 blockade combination therapy